

## Erratum to: A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma

Raffaele Addeo · Michele Caraglia · M. Serena De Santi · Liliana Montella ·  
Alberto Abbruzzese · Ciro Parlato · Bruno Vincenzi · Marco Carraturo ·  
Vincenzo Faiola · Michele Genovese · Gregorio Cennamo · Salvatore Del Prete

Published online: 21 September 2010  
© Springer Science+Business Media, LLC. 2010

### Erratum to: J Neurooncol DOI 10.1007/s11060-010-0329-z

The Abstract section of the original publication contains the following two errors:

- right column, lines 6–7: “...then every 3 weeks at 100 mg/m<sup>2</sup>...” should read “...then every 4 weeks at 80 mg/m<sup>2</sup>...”.

- right column, lines 16–17: “Progression-free survival at 6 months was 61%.” should read “Progression-free survival at 6 months was 39%.”.

The online version of the original article can be found under doi:  
[10.1007/s11060-010-0329-z](https://doi.org/10.1007/s11060-010-0329-z).

R. Addeo (✉) · L. Montella · G. Cennamo · S. D. Prete  
Oncology Department, “S. Giovanni di Dio” Hospital, ASL  
Napoli2 Nord Via Giovanni XXIII, 80028 Frattaminore,  
Naples, Italy  
e-mail: lelloaddeo@alice.it

M. Caraglia · A. Abbruzzese  
Department of Biochemistry and Biophysics, Second University  
of Naples, Via Costantinopoli, 16-80138 Naples, Italy

M. S. De Santi · M. Genovese  
Neurosurgery Department, “Umberto I” Hospital ASL SA, V.  
F. Ricco, 84014 Nocera Inferiore, Salerno, Italy

C. Parlato  
Department of Neurosurgery, Second University of Naples,  
Viale Colli Aminei 21, Naples, Italy

B. Vincenzi  
Section of Oncology, Campus Biomedico University,  
Rome, Italy

M. Carraturo  
Radiotherapy Unit, ASL Napoli 2 Nord, Acerra, Naples, Italy

V. Faiola  
Oncology Unit, AORN “Ruggi D’Aragona” Hospital,  
Salerno, Italy